Protara Therapeutics, Inc. TARA

Rank #2057 · Nasdaq · $0.1B market cap

Audited by Ernst & Young LLP, no going-concern flag in the latest filing.

Score

35.2

P/E

-3.1

P/B

2.04

ROE

-65.3%

Op. Margin

–%

Debt Ratio

21%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆

Weak

P/E -3.1x, P/B 2.04x. Ranks in the top 65% of the universe.

Profitability ★☆☆☆☆

Poor

ROE -65.3%. Ranks in the top 91% of the universe.

Safety ★★★★☆

Excellent

Debt ratio 21%. Ranks in the top 13% of the universe. Under 100% is generally considered a safe level.

Growth –

No data

Not enough historical filings to compute year-over-year growth yet.

Safety is the relative strength · Profitability is the relative weakness (relative to this universe).

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2014	$0.0B	$-0.0B	$-0.0B	$-0.1B	-271.2	-13
2015	$0.0B	$-0.0B	$-0.0B	$-0.1B	-241.6	-3
2016	$0.0B	$-0.0B	$-0.0B	$-0.1B	-257.1	-4
2017	–	$-0.0B	$-0.0B	$0.1B	–	6
2018	–	$-0.0B	$-0.0B	$0.1B	–	15
2019	–	$-0.0B	$-0.0B	$0.0B	–	9
2020	–	$-0.0B	$-0.0B	$0.0B	–	70
2021	–	$-0.0B	$-0.0B	$-0.0B	–	-184
2022	–	$-0.0B	$-0.0B	$0.2B	–	5
2023	–	$-0.1B	$-0.1B	$0.2B	–	7
2024	–	$-0.0B	$-0.0B	$0.1B	–	10
2025	–	$-0.0B	$-0.0B	$0.1B	–	21